Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
3 July 2017 |
Main ID: |
EUCTR2013-003201-26-ES |
Date of registration:
|
04/07/2014 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Evaluation of Dual Therapy with Dabigatran vs. Triple Therapy with Warfarin in Patients with AF that undergo a PCI with Stenting
|
Scientific title:
|
A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. triple therapy strategy with warfarin (INR 2.0 - 3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting - RE-DUAL PCI |
Date of first enrolment:
|
06/08/2014 |
Target sample size:
|
10500 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-003201-26 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: no
Other: no
Number of treatment arms in the trial: 3
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Argentina
|
Australia
|
Austria
|
Belgium
|
Brazil
|
Bulgaria
|
Canada
|
Chile
|
China
|
Colombia
|
Croatia
|
Czech Republic
|
Denmark
|
Finland
|
France
|
Germany
|
Greece
|
Hong Kong
|
Hungary
|
Ireland
|
Israel
|
Italy
|
Japan
|
Korea, Republic of
|
Mexico
|
Netherlands
|
New Zealand
|
Norway
|
Poland
|
Portugal
|
Singapore
|
Slovakia
|
Slovenia
|
Spain
|
Sweden
|
Taiwan
|
Thailand
|
Turkey
|
United Kingdom
|
United States
|
Contacts
|
Name:
|
QPRE PSC CT Information Disclosure
|
Address:
|
Binger Strasse 173
55216
Ingelheim am Rhein
Germany |
Telephone:
|
+34934045100 |
Email:
|
clintriage.rdg@boehringer-ingelheim.com |
Affiliation:
|
Boehringer Ingelheim Pharma GmbH & Co.KG |
|
Name:
|
QPRE PSC CT Information Disclosure
|
Address:
|
Binger Strasse 173
55216
Ingelheim am Rhein
Germany |
Telephone:
|
+34934045100 |
Email:
|
clintriage.rdg@boehringer-ingelheim.com |
Affiliation:
|
Boehringer Ingelheim Pharma GmbH & Co.KG |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: - Male or female patients aged >=18 years - Patients with Non Valvular Atrial Fibrillation - Patient presenting with: An ACS (STEMI, NonSTEMI [NSTEMI] or unstable angina [UA]) that was successfully treated by PCI and stenting (either Bare Metal Stent or Drug Eluting Stent)
Or
Stable Coronary Artery Disease with at least one lesion eligible for PCI that was successfully treated by elective PCI and stenting (either BMS or DES)
- The patient must be able to give informed consent in accordance with International Conference on Harmonisation Good Clinical Practice guidelines and local legislation and/or regulations. Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 1300 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 7220
Exclusion criteria: - Patients with a mechanical or biological heart valve prosthesis - Cardiogenic shock during current hospitalisation - Stroke within 1 month prior to screening visit - Patients who have had major surgery within the month prior to screening - Gastrointestinal haemorrhage within one month prior to screening, unless, in the opinion of the Investigator, the cause has been permanently eliminated - Major bleeding episode including life-threatening bleeding episode in one month prior to screening visit - Anaemia (haemoglobin <10g/dL) or thrombocytopenia including heparin-induced thrombocytopenia (platelet count <100 x 109/L) at screening - Severe renal impairment (estimated CrCl calculated by Cockcroft-Gault equation) <30mL/min at screening - Active liver disease
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting MedDRA version: 17.0
Level: PT
Classification code 10003658
Term: Atrial fibrillation
System Organ Class: 10007541 - Cardiac disorders
MedDRA version: 17.0
Level: PT
Classification code 10065608
Term: Percutaneous coronary intervention
System Organ Class: 10042613 - Surgical and medical procedures
|
Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
|
Intervention(s)
|
Trade Name: Pradaxa Product Name: dabigatran etexilate, 110 mg Product Code: BIBR 1048 MS Pharmaceutical Form: Capsule, hard INN or Proposed INN: DABIGATRAN ETEXILATE MESILATE Current Sponsor code: BIBR 1048 MS Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 110-
Trade Name: Pradaxa Product Name: dabigatran etexilate, 150 mg Product Code: BIBR 1048 MS Pharmaceutical Form: Capsule, hard INN or Proposed INN: DABIGATRAN ETEXILATE MESILATE Current Sponsor code: BIBR 1048 MS Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-
Trade Name: Warfarin 1mg Tablets Product Name: Warfarin Pharmaceutical Form: Tablet INN or Proposed INN: warfarin Other descriptive name: WARFARIN SODIUM Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1-
Trade Name: Warfarin 3mg Tablets Product Name: Warfarin Pharmaceutical Form: Tablet INN or Proposed INN: warfarin Other descriptive name: WARFARIN SODIUM Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3-
Trade Name: Warfarin 5 mg Tablets Product Name: Warfarin Pharmaceutical Form: Tablet INN or Proposed INN: warfarin Other descriptive name: WARFARIN SODIUM Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5-
|
Primary Outcome(s)
|
Main Objective: To compare a dual antithrombotic treatment regimen of 110mg dabigatran etexilate twice a day (b.i.d.) plus clopidogrel or ticagrelor and 150mg dabigatran etexilate b.i.d. plus clopidogrel or ticagrelor with triple antithrombotic therapy combination of warfarin plus clopidogrel or ticagrelor plus Aspirin <= 100mg once a day (q.d.) in patients with Atrial Fibrillation (AF) that undergo a Percutaneous Coronary Intervention (PCI) with stenting.
|
Timepoint(s) of evaluation of this end point: 1: up to 30 months
2: up to 30 months
|
Secondary Objective: Not applicable
|
Primary end point(s): 1: Time to death or first thrombotic event (all death, myocardial infarction (MI), stroke/systemic embolism (SE))
2: Time to first International Society of Thrombosis and Haemostasis Major Bleeding Event
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: 1: up to 30 months
2: up to 30 months
3: up to 30 months
4: up to 30 months
5: up to 30 months
6: up to 30 months
7: up to 30 months
8: up to 30 months
9: up to 30 months
10: up to 30 months
|
Secondary end point(s): 1: Time to event for individual outcome events - All death
2: Time to event for individual outcome events - Myocardial Infarction
3: Time to event for individual outcome events - Stroke
4: Time to event for individual outcome events - SE
5: Time to event for individual outcome events - Stent Thrombosis
6: Time to event for the composite endpoint of death + MI + stroke
7: Time to event for repeated revascularisation by Percutaneous Coronary Intervention/Coronary Artery Bypass Graft
8: Time to event for individual outcome events - Cardiovascular death
9: Time to event for individual outcome events - Non-cardiovascular death
10: Time to event for individual outcome events - Undetermined cause of death
|
Secondary ID(s)
|
2013-003201-26-SE
|
1160.186
|
Source(s) of Monetary Support
|
Boehringer Ingelheim España, S.A.
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|